HORSHAM, Pa.--(BUSINESS WIRE)--Nucleonics, Inc., a privately held biotechnology company focused on the development of novel RNA interference-based therapeutics, today issued a statement regarding the July 20, 2007 decision by the US Court of Appeals for the Federal Circuit to affirm the District Court’s grant of Benitec’s motion to dismiss its patent infringement suit against Nucleonics. Nucleonics strongly believes that the dismissal of Nucleonics’ declaratory judgment counterclaims of invalidity and unenforceability was wrongly decided. Nucleonics also said that separate from the litigation, Nucleonics is pursuing ex parte re-examination of Benitec’s US 6,573,099 patent in the US Patent and Trademark Office.
